| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HLA Antigens | 15 | 2026 | 221 | 2.780 |
Why?
|
| Graft Rejection | 11 | 2026 | 540 | 1.760 |
Why?
|
| Kidney Transplantation | 6 | 2024 | 553 | 1.660 |
Why?
|
| Isoantibodies | 5 | 2026 | 59 | 1.630 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 9 | 2023 | 1278 | 1.150 |
Why?
|
| Transplantation | 2 | 2018 | 24 | 1.140 |
Why?
|
| Histocompatibility Testing | 5 | 2025 | 108 | 1.120 |
Why?
|
| Chimerism | 2 | 2021 | 29 | 1.070 |
Why?
|
| Glutathione Transferase | 1 | 2026 | 146 | 0.880 |
Why?
|
| Heart Transplantation | 5 | 2026 | 799 | 0.840 |
Why?
|
| BK Virus | 1 | 2024 | 58 | 0.800 |
Why?
|
| Viremia | 1 | 2024 | 130 | 0.790 |
Why?
|
| Organ Transplantation | 2 | 2025 | 169 | 0.780 |
Why?
|
| Polyomavirus Infections | 1 | 2024 | 87 | 0.780 |
Why?
|
| Laboratories | 1 | 2022 | 80 | 0.680 |
Why?
|
| Hematologic Neoplasms | 5 | 2020 | 315 | 0.620 |
Why?
|
| Cell Proliferation | 6 | 2012 | 2461 | 0.610 |
Why?
|
| B7 Antigens | 1 | 2018 | 16 | 0.570 |
Why?
|
| Tissue and Organ Procurement | 1 | 2021 | 252 | 0.550 |
Why?
|
| Pleural Neoplasms | 3 | 2025 | 83 | 0.520 |
Why?
|
| Epitopes | 1 | 2018 | 323 | 0.500 |
Why?
|
| Polymorphism, Single Nucleotide | 4 | 2021 | 2827 | 0.500 |
Why?
|
| Protein Kinases | 3 | 2008 | 312 | 0.490 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2021 | 889 | 0.480 |
Why?
|
| Leukemia, Myeloid, Acute | 4 | 2020 | 607 | 0.480 |
Why?
|
| OX40 Ligand | 1 | 2015 | 9 | 0.460 |
Why?
|
| Tissue Donors | 4 | 2021 | 503 | 0.460 |
Why?
|
| Transplantation Tolerance | 2 | 2012 | 11 | 0.450 |
Why?
|
| Histocompatibility Antigens Class I | 5 | 2008 | 108 | 0.440 |
Why?
|
| T-Lymphocytes | 5 | 2018 | 1716 | 0.420 |
Why?
|
| Endothelial Cells | 4 | 2008 | 521 | 0.420 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2016 | 174 | 0.420 |
Why?
|
| Homozygote | 1 | 2015 | 533 | 0.400 |
Why?
|
| Transplant Recipients | 2 | 2026 | 229 | 0.380 |
Why?
|
| Cytokines | 1 | 2018 | 1332 | 0.370 |
Why?
|
| Genes, MHC Class II | 1 | 2012 | 12 | 0.370 |
Why?
|
| Signal Transduction | 6 | 2008 | 4664 | 0.370 |
Why?
|
| Endothelium, Vascular | 4 | 2008 | 468 | 0.360 |
Why?
|
| Cell Survival | 4 | 2008 | 825 | 0.350 |
Why?
|
| Transplantation, Homologous | 8 | 2023 | 667 | 0.340 |
Why?
|
| Bone Marrow Cells | 1 | 2012 | 243 | 0.330 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 2 | 2008 | 136 | 0.320 |
Why?
|
| Graft vs Host Disease | 5 | 2023 | 691 | 0.320 |
Why?
|
| Mesothelioma | 2 | 2024 | 96 | 0.310 |
Why?
|
| Humans | 40 | 2026 | 130534 | 0.300 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2010 | 253 | 0.280 |
Why?
|
| MicroRNAs | 2 | 2017 | 888 | 0.280 |
Why?
|
| H-2 Antigens | 1 | 2008 | 11 | 0.270 |
Why?
|
| HLA-A Antigens | 1 | 2008 | 33 | 0.270 |
Why?
|
| Integrins | 1 | 2008 | 89 | 0.260 |
Why?
|
| HLA-DQ Antigens | 1 | 2026 | 21 | 0.230 |
Why?
|
| Immunogenetics | 1 | 2025 | 10 | 0.230 |
Why?
|
| Kidney Glomerulus | 2 | 2017 | 80 | 0.220 |
Why?
|
| Middle Aged | 17 | 2025 | 28424 | 0.220 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2018 | 1069 | 0.220 |
Why?
|
| Disease-Free Survival | 4 | 2015 | 903 | 0.220 |
Why?
|
| Aged | 14 | 2025 | 20899 | 0.220 |
Why?
|
| B-Lymphocytes | 2 | 2018 | 508 | 0.210 |
Why?
|
| GPI-Linked Proteins | 1 | 2024 | 109 | 0.210 |
Why?
|
| Antibodies, Monoclonal | 2 | 2008 | 978 | 0.200 |
Why?
|
| Gene Expression Profiling | 1 | 2010 | 1800 | 0.190 |
Why?
|
| Tumor Virus Infections | 1 | 2024 | 131 | 0.190 |
Why?
|
| Primary Graft Dysfunction | 1 | 2023 | 41 | 0.190 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2023 | 125 | 0.180 |
Why?
|
| Female | 18 | 2026 | 70563 | 0.180 |
Why?
|
| Reperfusion Injury | 1 | 2023 | 107 | 0.180 |
Why?
|
| Neuromyelitis Optica | 1 | 2022 | 34 | 0.180 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 2 | 2012 | 27 | 0.170 |
Why?
|
| Treatment Outcome | 8 | 2024 | 12854 | 0.170 |
Why?
|
| Algorithms | 2 | 2018 | 1669 | 0.170 |
Why?
|
| Lung Neoplasms | 2 | 2024 | 1545 | 0.170 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 2 | 2012 | 91 | 0.170 |
Why?
|
| Microsatellite Repeats | 1 | 2021 | 204 | 0.170 |
Why?
|
| Living Donors | 2 | 2012 | 110 | 0.170 |
Why?
|
| Genotype | 2 | 2026 | 2589 | 0.160 |
Why?
|
| Genetic Therapy | 1 | 2025 | 711 | 0.160 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2025 | 814 | 0.160 |
Why?
|
| Double-Blind Method | 1 | 2024 | 1613 | 0.160 |
Why?
|
| Transplantation Conditioning | 4 | 2023 | 327 | 0.160 |
Why?
|
| Male | 17 | 2025 | 64598 | 0.160 |
Why?
|
| Flow Cytometry | 1 | 2022 | 765 | 0.150 |
Why?
|
| Retrospective Studies | 11 | 2024 | 17653 | 0.150 |
Why?
|
| Siblings | 4 | 2014 | 201 | 0.150 |
Why?
|
| Immunotherapy | 1 | 2024 | 761 | 0.150 |
Why?
|
| Immunoglobulin G | 1 | 2022 | 782 | 0.140 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2018 | 73 | 0.140 |
Why?
|
| Mice, Inbred BALB C | 3 | 2010 | 977 | 0.140 |
Why?
|
| Lung Transplantation | 1 | 2023 | 359 | 0.140 |
Why?
|
| Serologic Tests | 1 | 2018 | 122 | 0.140 |
Why?
|
| Donor Selection | 1 | 2018 | 60 | 0.130 |
Why?
|
| Young Adult | 6 | 2026 | 10036 | 0.130 |
Why?
|
| Czechoslovakia | 2 | 2018 | 2 | 0.130 |
Why?
|
| Capillaries | 1 | 2017 | 63 | 0.130 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2018 | 141 | 0.130 |
Why?
|
| Adult | 11 | 2024 | 31121 | 0.130 |
Why?
|
| Biomarkers, Tumor | 1 | 2024 | 1581 | 0.120 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2018 | 637 | 0.120 |
Why?
|
| Blood Group Incompatibility | 1 | 2016 | 28 | 0.120 |
Why?
|
| Oncogene Proteins v-myb | 1 | 2015 | 4 | 0.120 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2018 | 205 | 0.120 |
Why?
|
| ABO Blood-Group System | 1 | 2016 | 61 | 0.120 |
Why?
|
| Proportional Hazards Models | 3 | 2016 | 1409 | 0.110 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2008 | 428 | 0.110 |
Why?
|
| Antigens, Neoplasm | 1 | 2018 | 393 | 0.110 |
Why?
|
| Survival Rate | 3 | 2016 | 2109 | 0.110 |
Why?
|
| Registries | 4 | 2018 | 1614 | 0.110 |
Why?
|
| Autoantibodies | 1 | 2017 | 436 | 0.110 |
Why?
|
| Antibodies | 2 | 2006 | 316 | 0.100 |
Why?
|
| Cells, Cultured | 3 | 2008 | 2883 | 0.100 |
Why?
|
| Antigens, CD | 1 | 2015 | 409 | 0.100 |
Why?
|
| End Stage Liver Disease | 1 | 2016 | 193 | 0.100 |
Why?
|
| Computational Biology | 1 | 2018 | 861 | 0.100 |
Why?
|
| Mice | 5 | 2025 | 18203 | 0.090 |
Why?
|
| Thrombotic Microangiopathies | 1 | 2013 | 49 | 0.090 |
Why?
|
| Skin Transplantation | 1 | 2012 | 56 | 0.090 |
Why?
|
| Retroviridae | 1 | 2012 | 182 | 0.090 |
Why?
|
| Phosphorylation | 4 | 2008 | 1570 | 0.090 |
Why?
|
| Immune Tolerance | 1 | 2012 | 149 | 0.090 |
Why?
|
| Mice, Inbred C57BL | 3 | 2010 | 4702 | 0.090 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 1 | 2011 | 35 | 0.090 |
Why?
|
| Genome-Wide Association Study | 1 | 2018 | 1829 | 0.080 |
Why?
|
| Remission Induction | 3 | 2020 | 306 | 0.080 |
Why?
|
| Transcriptome | 1 | 2018 | 1098 | 0.080 |
Why?
|
| Isoantigens | 1 | 2010 | 22 | 0.080 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2018 | 2024 | 0.080 |
Why?
|
| Luciferases | 1 | 2010 | 126 | 0.080 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2012 | 236 | 0.080 |
Why?
|
| Czech Republic | 3 | 2020 | 11 | 0.080 |
Why?
|
| Focal Adhesion Protein-Tyrosine Kinases | 2 | 2007 | 25 | 0.080 |
Why?
|
| Prognosis | 2 | 2018 | 4866 | 0.080 |
Why?
|
| 3' Untranslated Regions | 1 | 2010 | 154 | 0.080 |
Why?
|
| Animals | 6 | 2025 | 33739 | 0.070 |
Why?
|
| Green Fluorescent Proteins | 1 | 2010 | 358 | 0.070 |
Why?
|
| RNA, Small Interfering | 2 | 2008 | 662 | 0.070 |
Why?
|
| Stem Cells | 1 | 2014 | 702 | 0.070 |
Why?
|
| Chemokine CCL2 | 1 | 2009 | 112 | 0.070 |
Why?
|
| Transfection | 1 | 2010 | 961 | 0.070 |
Why?
|
| Case-Control Studies | 1 | 2015 | 3351 | 0.070 |
Why?
|
| Histocompatibility Antigen H-2D | 1 | 2008 | 3 | 0.070 |
Why?
|
| Blotting, Western | 1 | 2010 | 1013 | 0.070 |
Why?
|
| Lymphocyte Activation | 1 | 2010 | 632 | 0.070 |
Why?
|
| Acyclovir | 1 | 2007 | 49 | 0.070 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 1205 | 0.070 |
Why?
|
| Cell Line | 2 | 2010 | 2552 | 0.070 |
Why?
|
| Immunization, Passive | 1 | 2008 | 120 | 0.070 |
Why?
|
| Ganciclovir | 1 | 2007 | 101 | 0.070 |
Why?
|
| Adolescent | 6 | 2020 | 20879 | 0.070 |
Why?
|
| Focal Adhesions | 1 | 2007 | 14 | 0.070 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2012 | 542 | 0.070 |
Why?
|
| RNA, Messenger | 1 | 2013 | 2544 | 0.060 |
Why?
|
| Tumor Microenvironment | 2 | 2025 | 711 | 0.060 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2010 | 459 | 0.060 |
Why?
|
| Valine | 1 | 2007 | 110 | 0.060 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2010 | 500 | 0.060 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2008 | 178 | 0.060 |
Why?
|
| Interleukin-6 | 1 | 2009 | 410 | 0.060 |
Why?
|
| Liver Transplantation | 1 | 2016 | 1134 | 0.060 |
Why?
|
| Multiprotein Complexes | 1 | 2008 | 195 | 0.060 |
Why?
|
| Enzyme Activation | 1 | 2008 | 576 | 0.060 |
Why?
|
| Ribosomal Protein S6 | 1 | 2006 | 14 | 0.060 |
Why?
|
| Cohort Studies | 1 | 2016 | 5048 | 0.060 |
Why?
|
| MAP Kinase Signaling System | 1 | 2008 | 301 | 0.060 |
Why?
|
| Cytomegalovirus | 1 | 2007 | 257 | 0.060 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2013 | 881 | 0.060 |
Why?
|
| Child, Preschool | 3 | 2020 | 15029 | 0.060 |
Why?
|
| Cytomegalovirus Infections | 1 | 2007 | 220 | 0.060 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2023 | 1266 | 0.060 |
Why?
|
| Cell Line, Tumor | 2 | 2025 | 3734 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2004 | 165 | 0.050 |
Why?
|
| B7-H1 Antigen | 1 | 2024 | 134 | 0.050 |
Why?
|
| Recurrence | 2 | 2020 | 1483 | 0.050 |
Why?
|
| Infant | 2 | 2016 | 13295 | 0.050 |
Why?
|
| Lung | 2 | 2023 | 1531 | 0.050 |
Why?
|
| Europe | 2 | 2014 | 364 | 0.050 |
Why?
|
| Aquaporin 4 | 1 | 2022 | 16 | 0.050 |
Why?
|
| Proteins | 1 | 2008 | 1006 | 0.050 |
Why?
|
| Mice, Transgenic | 1 | 2008 | 2323 | 0.050 |
Why?
|
| Benzimidazoles | 1 | 2003 | 156 | 0.050 |
Why?
|
| Antiviral Agents | 1 | 2007 | 805 | 0.040 |
Why?
|
| Filgrastim | 2 | 2012 | 13 | 0.040 |
Why?
|
| Pyrroles | 1 | 2003 | 188 | 0.040 |
Why?
|
| Potassium Channels | 1 | 2022 | 154 | 0.040 |
Why?
|
| Child | 3 | 2020 | 26237 | 0.040 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2025 | 618 | 0.040 |
Why?
|
| Haplotypes | 1 | 2022 | 517 | 0.040 |
Why?
|
| Societies, Medical | 1 | 2025 | 793 | 0.040 |
Why?
|
| Unrelated Donors | 1 | 2020 | 72 | 0.040 |
Why?
|
| Mice, Knockout | 1 | 2008 | 3820 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2023 | 1243 | 0.040 |
Why?
|
| Predictive Value of Tests | 1 | 2024 | 2298 | 0.040 |
Why?
|
| Receptors, KIR | 1 | 2018 | 12 | 0.040 |
Why?
|
| Prospective Studies | 3 | 2018 | 6424 | 0.040 |
Why?
|
| Costimulatory and Inhibitory T-Cell Receptors | 1 | 2018 | 6 | 0.030 |
Why?
|
| Transcription Factors | 1 | 2008 | 2403 | 0.030 |
Why?
|
| Bone Marrow Transplantation | 1 | 2001 | 588 | 0.030 |
Why?
|
| Recombinant Proteins | 2 | 2012 | 1319 | 0.030 |
Why?
|
| Pleura | 1 | 2018 | 27 | 0.030 |
Why?
|
| Research Report | 1 | 2018 | 73 | 0.030 |
Why?
|
| DNA | 1 | 2003 | 1397 | 0.030 |
Why?
|
| Dendritic Cells | 1 | 2020 | 436 | 0.030 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2018 | 127 | 0.030 |
Why?
|
| Proteogenomics | 1 | 2018 | 111 | 0.030 |
Why?
|
| Mass Spectrometry | 1 | 2018 | 358 | 0.030 |
Why?
|
| In Vitro Techniques | 1 | 2017 | 808 | 0.030 |
Why?
|
| src-Family Kinases | 2 | 2007 | 93 | 0.030 |
Why?
|
| Single-Cell Analysis | 1 | 2018 | 348 | 0.030 |
Why?
|
| Melphalan | 1 | 2014 | 45 | 0.030 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2007 | 335 | 0.030 |
Why?
|
| Antilymphocyte Serum | 1 | 2014 | 44 | 0.030 |
Why?
|
| Age Factors | 2 | 2016 | 2818 | 0.030 |
Why?
|
| Alemtuzumab | 1 | 2014 | 89 | 0.020 |
Why?
|
| Incidence | 2 | 2014 | 3336 | 0.020 |
Why?
|
| Probability | 1 | 2013 | 305 | 0.020 |
Why?
|
| Calcineurin Inhibitors | 1 | 2013 | 25 | 0.020 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2013 | 49 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2007 | 480 | 0.020 |
Why?
|
| ADAMTS13 Protein | 1 | 2013 | 64 | 0.020 |
Why?
|
| ADAM Proteins | 1 | 2013 | 78 | 0.020 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2013 | 111 | 0.020 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2013 | 103 | 0.020 |
Why?
|
| Mice, Inbred CBA | 1 | 2010 | 26 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2014 | 1376 | 0.020 |
Why?
|
| Whole-Body Irradiation | 1 | 2010 | 60 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2014 | 567 | 0.020 |
Why?
|
| United States | 1 | 2025 | 12009 | 0.020 |
Why?
|
| Adoptive Transfer | 1 | 2010 | 235 | 0.020 |
Why?
|
| Risk Factors | 1 | 2023 | 11012 | 0.020 |
Why?
|
| Forkhead Transcription Factors | 1 | 2010 | 370 | 0.020 |
Why?
|
| Disease Progression | 1 | 2013 | 2192 | 0.020 |
Why?
|
| Receptors, Fibroblast Growth Factor | 1 | 2007 | 57 | 0.020 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2006 | 71 | 0.010 |
Why?
|
| RNA Interference | 1 | 2007 | 491 | 0.010 |
Why?
|
| Actins | 1 | 2007 | 321 | 0.010 |
Why?
|
| bcl-Associated Death Protein | 1 | 2004 | 4 | 0.010 |
Why?
|
| Focal Adhesion Kinase 1 | 1 | 2004 | 24 | 0.010 |
Why?
|
| bcl-X Protein | 1 | 2004 | 32 | 0.010 |
Why?
|
| Androstadienes | 1 | 2004 | 50 | 0.010 |
Why?
|
| Titrimetry | 1 | 2003 | 6 | 0.010 |
Why?
|
| Hydroxybutyrates | 1 | 2003 | 31 | 0.010 |
Why?
|
| Cross-Linking Reagents | 1 | 2003 | 47 | 0.010 |
Why?
|
| Fluorometry | 1 | 2003 | 27 | 0.010 |
Why?
|
| Acute Disease | 1 | 2006 | 1152 | 0.010 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2004 | 219 | 0.010 |
Why?
|
| Graft Survival | 1 | 2005 | 459 | 0.010 |
Why?
|
| Nucleic Acid Conformation | 1 | 2003 | 177 | 0.010 |
Why?
|
| Biopsy | 1 | 2006 | 1229 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2011 | 5184 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2010 | 2320 | 0.010 |
Why?
|
| Imidazoles | 1 | 2003 | 219 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2004 | 826 | 0.010 |
Why?
|
| Actuarial Analysis | 1 | 2001 | 27 | 0.010 |
Why?
|
| Kinetics | 1 | 2003 | 1087 | 0.010 |
Why?
|
| Myocardium | 1 | 2006 | 847 | 0.010 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2004 | 597 | 0.010 |
Why?
|
| Time Factors | 1 | 2010 | 6168 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 2004 | 994 | 0.010 |
Why?
|
| Cause of Death | 1 | 2001 | 502 | 0.010 |
Why?
|
| Biomarkers | 1 | 2006 | 3366 | 0.010 |
Why?
|